Palonosetron Accord

RSS

palonosetron

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Palonosetron Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Palonosetron Accord.

For practical information about using Palonosetron Accord, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 19/03/2019

Authorisation details

Product details
Name
Palonosetron Accord
Agency product number
EMEA/H/C/004129
Active substance
Palonosetron
International non-proprietary name (INN) or common name
palonosetron
Therapeutic area (MeSH)
  • Vomiting
  • Nausea
  • Cancer
Anatomical therapeutic chemical (ATC) code
A04AA05
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Accord Healthcare S.L.U.
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
26/05/2016
Contact address

World Trade Center
Moll de Barcelona
s/n, Edifici Est 6ª planta
08039 Barcelona
Spain

Product information

01/03/2019 Palonosetron Accord - EMEA/H/C/004129 - T/0004

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antiemetics and antinauseants

Therapeutic indication

Palonosetron Accord is indicated in adults for:

  • the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,
  • the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Palonosetron Accord is indicated in paediatric patients 1 month of age and older for:

  • The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Assessment history

How useful was this page?

Add your rating